argenx announces launch of proposed global offering
March 22, 2022 16:15 ET
|
argenx SE
Regulated information — Inside information March 22, 2022 Breda, the Netherlands — argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people...
argenx Reports Full Year 2021 Financial Results and Provides Fourth Quarter Business Update
March 03, 2022 01:00 ET
|
argenx SE
VYVGART® (efgartigimod alfa-fcab) approved in the U.S. and Japan as the first-and-only neonatal Fc receptor (FcRn) blocker; U.S. commercial launch underway Topline results from Phase 3 bridging...
argenx to Present at the 42nd Annual Cowen Health Care Conference
February 28, 2022 01:00 ET
|
argenx SE
February 28, 2022Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,...
argenx to Report Full Year 2021 Financial Results and Fourth Quarter Business Update on March 3, 2022
February 24, 2022 01:00 ET
|
argenx SE
February 24, 2022Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,...
argenx to Present at the 11th Annual SVB Leerink Global Healthcare Conference
February 10, 2022 01:00 ET
|
argenx SE
February 10, 2022Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,...
argenx to Present at 40th Annual J.P. Morgan Healthcare Conference
January 03, 2022 01:00 ET
|
argenx SE
January 3, 2022Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today...
argenx to Present at Upcoming Investor Conferences
November 10, 2021 01:00 ET
|
argenx SE
November 10, 2021Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and...
argenx Reports Third Quarter 2021 Financial Results and Provides Business Update
October 28, 2021 01:00 ET
|
argenx SE
– U.S. and Japan commercial teams fully staffed ahead of potential launches of efgartigimod in generalized myasthenia gravis (gMG) – – Signed partnership agreement with Medison for distribution...
argenx to Report Third Quarter 2021 Financial Results and Business Update on October 28, 2021
October 21, 2021 01:00 ET
|
argenx SE
October 21, 2021Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and...
argenx to Highlight Potential First-in-Class FcRn Antagonist Efgartigimod at Upcoming Neuromuscular Meetings
October 08, 2021 01:00 ET
|
argenx SE
Additional data from Phase 3 ADAPT trial demonstrate consistent depth of response across first two treatment cycles as measured by minimal symptom expression Additional ADAPT data also show...